We used transcriptome-wide association approaches to inform our drug repurposing inquiries. As recommended40, we attempted to limit tissue biases inherent to these approaches by constraining our sphere of interest to brain regions that were associated with PTSD severity through our partitioned heritability analyses. Nonetheless, the drug repurposing propositions, while hypothesis-generating and intriguing, are just that. They are one piece of information that might increase interest in testing the proposed drug classes in patients with PTSD; they must be buttressed by additional preclinical models, postmortem PTSD brain studies71, and complementary bioinformatic approaches72 supporting their use, as well as serious consideration of their safety in this population. We also remind readers that the present analyses rested solely on GWAS, thereby limiting inquiry to common genetic variants (to MAF 0.01, which still capture significant heritable variance) and that roles for rare variants and structural variation should also be explored. Epigenetic factors almost certainly also play a role in a disorder such as PTSD10,73, which has traumatic stress as its precursor. Many other functional genomics tools can and should be brought to bear on
